Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non‐Viral CAR ‐ NK Cell Engineering
Cell Proliferation · 2025
DOI: 10.1111/cpr.13791 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Proliferation, 2025. Verfasst von Zhaokai Zhou und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Killer Cells, Natural, Neoplasms, Receptors, Chimeric Antigen, Cell Engineering. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Provincial Science and Technology Research Project.
Abstract (Originalsprache)
The recent advancements in cancer immunotherapy have spotlighted the potential of natural killer (NK) cells, particularly chimeric antigen receptor (CAR)–transduced NK cells. These cells, pivotal in innate immunity, offer a rapid and potent response against cancer cells and pathogens without the need for prior sensitization or recognition of peptide antigens. Although NK cell genetic modification is evolving, the viral transduction method continues to be inefficient and fraught with risks, often resulting in cytotoxic outcomes and the possibility of insertional mutagenesis. Consequently, there has been a surge in the development of non‐viral transfection technologies to overcome these challenges in NK cell engineering. Non‐viral approaches for CAR‐NK cell generation are becoming increasingly essential. Cutting‐edge techniques such as trogocytosis, electroporation, lipid nanoparticle (LNP) delivery, clustered regularly interspaced short palindromic repeats–associated protein 9 (CRISPR‐Cas9) gene editing and transposons not only enhance the efficiency and safety of CAR‐NK cell engineering but also open new avenues for novel therapeutic possibilities. Additionally, the infusion of technologies already successful in CAR T‐cell therapy into the CAR‐NK paradigm holds immense potential for further advancements. In this review, we present an overview of the potential of NK cells in cancer immunotherapies, as well as non‐viral transfection technologies for engineering NK cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- The Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
ORCID-Profile: Peng Luo, Quan Cheng, Xinwei Han, Zaoqu Liu
Förderung
- Henan Provincial Science and Technology Research Project
Zitieren
APA
Zhou, Z., Chen, Y., Ba, Y., Xu, H., Zuo, A., Liu, S., Zhang, Y., Weng, S., Ren, Y., Luo, P., Cheng, Q., Zuo, L., Zhu, S., Zhou, X., Zhang, C., Chen, Y., Han, X., Pan, T., & Liu, Z. (2025). Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non‐Viral CAR ‐ NK Cell Engineering. Cell Proliferation. https://doi.org/10.1111/cpr.13791
Vancouver
Zhou Z, Chen Y, Ba Y, Xu H, Zuo A, Liu S, et al. Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non‐Viral CAR ‐ NK Cell Engineering. Cell Proliferation. 2025. doi:10.1111/cpr.13791
BibTeX
@article{Zhou2025,
author = {Zhou, Zhaokai and Chen, Yifeng and Ba, Yuhao and Xu, Hui and Zuo, Anning and Liu, Shutong and Zhang, Yuyuan and Weng, Siyuan and Ren, Yuqing and Luo, Peng and Cheng, Quan and Zuo, Lulu and Zhu, Shanshan and Zhou, Xing and Zhang, Chuhan and Chen, Yukang and Han, Xinwei and Pan, Teng and Liu, Zaoqu},
title = {Revolutionising Cancer Immunotherapy: Advancements and Prospects in Non‐Viral CAR ‐ NK Cell Engineering},
journal = {Cell Proliferation},
year = {2025},
doi = {10.1111/cpr.13791}
}
EUVIMED